Department of Physiology and Medicine, Division of Cardiology, University of California at Los Angeles, UCLA School of Medicine, Los Angeles, California 90095, USA.
Mol Cell Proteomics. 2011 May;10(5):M110.006122. doi: 10.1074/mcp.M110.006122. Epub 2011 Feb 25.
Myocardial proteasomes are comprised of 20S core particles and 19S regulatory particles, which together carry out targeted degradation of cardiac proteins. The 19S complex is unique among the regulators of proteasomes in that it affects both the capacity and specificity of protein degradation. However, a comprehensive molecular characterization of cardiac 19S complexes is lacking. In this investigation, we tailored a multidimensional chromatography-based purification strategy to isolate structurally intact and functionally viable 19S complexes from murine hearts. Two distinct subpopulations of 19S complexes were isolated based upon (1) potency of activating 20S proteolytic activity, and (2) molecular composition using a combination of immuno-detection, two-dimensional-differential gel electrophoresis, and MS-based approaches. Heat shock protein 90 (Hsp90) was identified to be characteristic to 19S subpopulation I. The physical interaction of Hsp90 with 19S complexes was demonstrated via multiple approaches. Inhibition of Hsp90 activity using geldanamycin or BIIB021 potentiated the ability of subpopulation I to activate 20S proteasomes in the murine heart, thus demonstrating functional specificity of Hsp90 in subpopulation I. This investigation has advanced our understanding of the molecular heterogeneity of cardiac proteasomes by identifying molecularly and functionally distinct cardiac 19S complexes. The preferential association of Hsp90 with 19S subpopulation I unveils novel targets for designing proteasome-based therapeutic interventions for combating cardiac disease.
心肌蛋白酶体由 20S 核心颗粒和 19S 调节颗粒组成,共同完成心脏蛋白质的靶向降解。19S 复合物在蛋白酶体调节剂中是独特的,因为它影响蛋白质降解的能力和特异性。然而,对心脏 19S 复合物的全面分子特征描述还很缺乏。在本研究中,我们设计了一种基于多维色谱的纯化策略,从鼠心中分离结构完整且功能活跃的 19S 复合物。根据(1)激活 20S 蛋白水解活性的效力,以及(2)使用免疫检测、二维差异凝胶电泳和基于 MS 的方法组合的分子组成,分离出两种不同的 19S 复合物亚群。热休克蛋白 90(Hsp90)被鉴定为 19S 亚群 I 的特征蛋白。通过多种方法证明了 Hsp90 与 19S 复合物的物理相互作用。使用格尔德霉素或 BIIB021 抑制 Hsp90 活性增强了亚群 I 激活鼠心中 20S 蛋白酶体的能力,从而证明了 Hsp90 在亚群 I 中的功能特异性。这项研究通过鉴定分子上和功能上不同的心脏 19S 复合物,推进了我们对心脏蛋白酶体分子异质性的理解。Hsp90 与 19S 亚群 I 的优先结合揭示了基于蛋白酶体的治疗干预心脏疾病的新靶点。